Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany

We determined adalimumab utilisation and associated drug costs in patients with ulcerative colitis (UC), focusing on patients requiring dose escalation. The retrospective cohort study analysed the de-identified prescription data of the Arvato Health Analytics (Munich, Germany) database (2010–2015) in adult UC patients undergoing adalimumab therapy. A total of 154 patients were newly treated with adalimumab (average 39.6 years, 53% females), with...